drugset / Trial / NCT06311929
Precision Adjuvant Therapy After Surgery for Hepatocellular Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
Vessels that encapsulate tumor clusters (VETC) is an invasive metastatic factor in HCC independent of the epithelial mesenchyme transition (EMT), and VETC-positive patients have a higher rate of postoperative recurrence. How to improve the prognosis of this group of patients is an urgent issue to be addressed.
Timeline
- Start
- 2024-04-01
- Primary completion
- 2027-12-31
- Completion
- 2028-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Lenvatinib | Small molecule | — | Oral |